<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE resolution PUBLIC "-//US Congress//DTDs/res.dtd//EN" "res.dtd">
<resolution resolution-stage="Introduced-in-House" dms-id="H92244D4720DF4D9DA2F17182CEEB1239" public-private="public" resolution-type="house-resolution" star-print="no-star-print" key="H"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>117 HRES 876 IH: Expressing the sense that the process behind Operation Warp Speed should be integrated within operations at the Food and Drug Administration.</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2022-01-19</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">IV</distribution-code><congress display="yes">117th CONGRESS</congress><session display="yes">2d Session</session><legis-num display="yes">H. RES. 876</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20220119">January 19, 2022</action-date><action-desc><sponsor name-id="B001248">Mr. Burgess</sponsor> submitted the following resolution; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>RESOLUTION</legis-type><official-title display="yes">Expressing the sense that the process behind Operation Warp Speed should be integrated within operations at the Food and Drug Administration.</official-title></form><resolution-body style="traditional" id="H1D9770601D384EC48433E97C82C607CD"><section display-inline="yes-display-inline" section-type="undesignated-section" id="H3398E632074147BE9C717F393C7E62DD"><enum/><text display-inline="yes-display-inline">That it is the sense of Congress that the Commissioner of Food and Drugs should—</text><paragraph id="H92B282277E5E44EAB74E8924413DF696"><enum>(1)</enum><text>to the extent scientifically and legally possible, integrate the process behind Operation Warp Speed into operations at the Food and Drug Administration;</text></paragraph><paragraph id="H0AF6B65430364C94ACD09CC70ED13361"><enum>(2)</enum><text display-inline="yes-display-inline">issue guidance identifying ways that drug and biological product innovation and development can be accelerated through clinical trials and the approval and licensure processes;</text></paragraph><paragraph id="H182524DB69C44D588D1F3E6311AC1A32"><enum>(3)</enum><text display-inline="yes-display-inline">for purposes of accelerating the approval of new drugs and biological products, cross-reference applicable safety and scientific data from approved drugs and licensed biological products; and</text></paragraph><paragraph id="HCAD9098DC0924BAEB5A28C6A8DFD6879"><enum>(4)</enum><text display-inline="yes-display-inline">collect interim data that would allow for parallel assessments of the safety and effectiveness of multiple drugs and biological products and the parallel approval or licensure of multiple drugs and biological products, including through the conduct of concurrent clinical trials.</text></paragraph></section></resolution-body></resolution> 

